John Valliant

Founder presso FUSN PHAR

Patrimonio netto: 7 M $ in data 31/03/2024

54 anni

Health Technology

Consumer Services

Posizioni attive di John Valliant

Società	Posizione	Inizio	Fine
FUSN PHAR	Director/Board Member	01/12/2014	-
	Chief Executive Officer	01/12/2014	-
	Founder	01/12/2014	-
Centre For Probe Development & Commercialization Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.	Director/Board Member	01/03/2008	-
	Founder	01/03/2008	-
	Independent Dir/Board Member	01/03/2008	-
McMaster University	Corporate Officer/Principal	01/01/1999	-

McMaster University

Doctorate Degree

Distribuzione geografica

Canada

Posizioni

Settori

Health Technology	3
Consumer Services	2

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Società quotate in Borsa	1
FUSN PHAR	Health Technology

Aziende private	1
Centre For Probe Development & Commercialization Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.	Health Technology

Aziende private

Health Technology